Skip to main content

MapLight Therapeutics, Inc.

corporate_fare Company Profile

MapLight Therapeutics, Inc.

MPLT·NASDAQ·Life Sciences·CIK 0001770069

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform aims to identify neural circuits causally linked to disease and target those circuits for therapeutic modulation. Our lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC). We are initially developing ML-007C-MA for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP). This candidate is designed to activate both M1 and M4 muscarinic receptors centrally to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. ML-007, either alone, co-administered, or co-formulated with PAC, has been evaluated in four Phase 1 trials, involving a total of 270 healthy participants and more than 1,500 doses of ML-007 administered. We are currently conducting ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for the treatment of schizophrenia. We expect this trial to reach its target enrollment of 300 participants in April 2026 and report topline results in the third quarter of 2026. Additionally, we are conducting VISTA, a Phase 2 trial evaluating ML-007C-MA for the treatment of ADP, and expect to report topline results in the second half of 2027.

MapLight Therapeutics, Inc. (NASDAQ:MPLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for MPLT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MPLT spans 10-Q, 8-K, 4, SCHEDULE 13D/A.

Recent high-impact activity:

  • MapLight 10-Q Confirms $51.6M Q3 Loss, $463.4M Cash Through 2028
  • MapLight Posts $51.6M Q3 Loss, $463.4M Cash Through 2028
  • MapLight Posts 97-Cent Quarterly Loss as Cash Burn Continues
  • Catalyst4 Boosts MapLight Stake with $83.4M Open-Market Purchase
  • Catalyst4 Discloses $83.4M PIPE Stake, Now Controls 49.9% of MapLight

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$161.15M
Diluted EPS
-$18.56
Op. Cash Flow
-$138.14M
Free Cash Flow
-$138.61M
Operating Income
-$169.08M
Cash & Equivalents
$46.73M
Debt / Equity
0.00×
Shares Outstanding
44.02M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-125072

Short Interest & Short Volume

10.31 days to cover

FINRA reported short interest of 3,251,647 shares in MPLT as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 10.3 days to cover at its recent average daily volume. On November 20, 2026, 45.4% of MPLT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,251,647 shares as of October 30, 2026
Change vs prior period▼ 2.1%
Days to cover10.31 at avg daily volume of 315,511
Daily short volume (FINRA facilities)45.4% of 132,700 shares on November 20, 2026
5-day average short volume44.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for MPLT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.

ATM program2 shelf registrations

New $400M Shelf Registration · New $100M ATM With Leerink

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$5.94
52-week range · as of 2026-11-16 $5.94 – $40.43
Market cap
$330.12M
Volume
357.9K (1.0× avg)
3-mo avg 375.2K
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MPLT - Latest Insights

MPLT
Nov 16, 2026, 7:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $5.94 info
Change: -$1.43 (-19%) info
Market Cap: $330.12M info
MPLT
Nov 16, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $5.94 info
Change: -$1.43 (-19%) info
Market Cap: $330.12M info
MPLT
Nov 16, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $5.94 info
Change: -$1.31 (-18%) info
Market Cap: $330.12M info
MPLT
Aug 18, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $5.94 info
Change: -$5.65 (-49%) info
Market Cap: $330.12M info
MPLT
Aug 18, 2026, 6:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.59
Real-time Price: $5.94 info
Change: -$5.65 (-49%) info
Market Cap: $330.12M info
MPLT
Aug 13, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.70
Real-time Price: $5.94 info
Change: -$5.76 (-49%) info
Market Cap: $330.12M info
MPLT
Aug 13, 2026, 4:51 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.70
Real-time Price: $5.94 info
Change: -$5.76 (-49%) info
Market Cap: $330.12M info
MPLT
Aug 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.82
Real-time Price: $5.94 info
Change: -$5.88 (-50%) info
Market Cap: $330.12M info
MPLT
Aug 13, 2026, 9:10 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.68
Real-time Price: $5.94 info
Change: -$5.74 (-49%) info
Market Cap: $330.12M info
MPLT
Aug 03, 2026, 9:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $12.82
Real-time Price: $5.94 info
Change: -$6.88 (-54%) info
Market Cap: $330.12M info
MPLT
Jul 31, 2026, 9:25 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $14.02
Real-time Price: $5.94 info
Change: -$8.08 (-58%) info
Market Cap: $330.12M info
MPLT
Jul 30, 2026, 9:08 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $14.50
Real-time Price: $5.94 info
Change: -$8.56 (-59%) info
Market Cap: $330.12M info
MPLT
Jul 30, 2026, 6:39 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $13.78
Real-time Price: $5.94 info
Change: -$7.84 (-57%) info
Market Cap: $330.12M info
MPLT
Jul 27, 2026, 8:27 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.42
Real-time Price: $5.94 info
Change: -$8.48 (-59%) info
Market Cap: $330.12M info
MPLT
Jul 27, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.62
Real-time Price: $5.94 info
Change: -$10.68 (-64%) info
Market Cap: $330.12M info
MPLT
Jul 17, 2026, 9:46 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $37.87
Real-time Price: $5.94 info
Change: -$31.93 (-84%) info
Market Cap: $330.12M info
MPLT
Jun 22, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $25.92
Real-time Price: $5.94 info
Change: -$19.98 (-77%) info
Market Cap: $330.12M info
MPLT
Jun 22, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.92
Real-time Price: $5.94 info
Change: -$19.98 (-77%) info
Market Cap: $330.12M info
MPLT
Jun 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.82
Real-time Price: $5.94 info
Change: -$22.88 (-79%) info
Market Cap: $330.12M info
MPLT
May 14, 2026, 4:27 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $29.29
Real-time Price: $5.94 info
Change: -$23.35 (-80%) info
Market Cap: $330.12M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets